Abstract

OBJECTIVES

Patients with poor lung function usually undergo cardiopulmonary exercise testing (CPET) and those with a predicted postoperative maximal oxygen consumption (VO2 max) of >10 ml/kg/min undergo lung resection surgery and still some complications are observed. We aimed to determine other parameters beyond VO2 able to predict postoperative complications in patients undergoing lung resection surgery.

METHODS

This is an observational study with longitudinal follow-up. Patients with forced expiratory volume in 1 second (FEV1) or diffusing capacity for carbon monoxide of <40% underwent CPET and those with VO2 max of >10 ml/kg/min were considered fit for surgery. Patients were followed up prospectively for 12 months and postoperative complications and survival were recorded. Physiological parameters obtained during CPET and pulmonary function tests were analysed.

RESULTS

Eighty-three chronic obstructive pulmonary disease (COPD) patients were evaluated for surgery between 2010 and 2015. Twenty-four patients were considered unfit for surgery and received an alternative therapy. Fifty-five patients had a VO2 max of >10 ml/kg/min and underwent lung surgery. Among them, 4% died and 41% developed complications postoperatively. Baseline minute ventilation to carbon dioxide output (VE/VCO2) slope was significantly higher among those who developed postoperative complications or died (P = 0.047). Furthermore, VE/VCO2 slope of >35 (at maximal exercise) was the single parameter most strongly associated with the probability of mortality and postoperative complications (hazard ratio 5.14) with a survival probability of 40% after 1 year of follow-up. In a multivariable model, VO2, VE/VCO2 slope of >35 and work load were independently associated with the probability of having an event.

CONCLUSIONS

VO2 is not the unique parameter to consider when CPET is performed to evaluate the postoperative risk of lung cancer surgery in COPD patients. The signs of ventilatory inefficiency such as VE/VCO2 slope predict complications better than VO2 does.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) patients frequently suffer from lung cancer, with resection surgery being the best therapeutic option. However, surgery is a challenge in these patients because they are at risk of postoperative complications and mortality [1] and a precise selection of fit for surgery patients is required. These postoperative complications include pneumonia, acute and chronic respiratory failure, mechanical ventilation of more than 48 h, pulmonary embolism, acute pulmonary oedema, acute myocardial infarction, lobar atelectasis requiring bronchoscopy as well as arrhythmias [2]. The preoperative physiological assessment of patients undergoing lung resection surgery should begin with cardiovascular evaluation and lung function assessment that includes spirometry to measure the FEV1 and the diffusing capacity for carbon monoxide (DLCO). Predicted postoperative (PPO) lung function should be calculated [3]. According to the current recommendations, if the % PPO FEV1 and % PPO DLCO values are both >60%, the patient is considered at low risk of anatomical lung resection [1], and no further tests are indicated. In general practice, it has been proposed that the shuttle walking test could be useful since it identifies patients with higher oxygen consumption (VO2) [4]. A cardiopulmonary exercise testing (CPET) is indicated when the PPO FEV1 and/or PPO DLCO are <30% [3]. A maximal oxygen consumption (VO2 max) of <10 ml/kg/min or 35% predicted indicates a high risk of mortality and long-term disability for major anatomical resection.

VO2 max is considered the most important parameter for the prediction of postoperative cardiopulmonary complications as previously described [5]. Smith et al. [2] showed that patients with VO2 max of less than 15 ml/kg/min had more frequent postoperative complications compared with patients with VO2 max of greater than 20 ml/kg/min assessed preoperatively by CPET and similar results were also described by Bechard and Wetstein [6]. Brunelli et al. [7] reported that VO2 max is a reliable predictor of postoperative pulmonary complications and that VO2 max of <12 ml/kg/min was related to mortality. Additionally, Win et al. [8] found that maximum VO2 percent of predicted was significantly related to postoperative cardiopulmonary complications and that complications were more frequently observed among those with VO2 max of <15 ml/kg/min.

Patients with VO2 max of <10 ml/kg/min are at high risk of postoperative mortality and non-surgical modalities of treatment should be offered for them [3]. However, VO2 max in the range of 10–20 ml/kg/min is still associated with moderate risk for postoperative complications [3] with higher incidence in COPD patients [1]. The aim of this work is to evaluate other parameters able to predict postoperative complications and mortality during CPET beyond VO2 max.

METHODS

Study design and ethics

This is a observational cross-sectional study with longitudinal follow-up that enrolled patients undergoing preoperative evaluation before surgical lung resection for lung cancer treatment according to the current guidelines [3] between 2010 and 2015 in a tertiary hospital. The study protocol was approved by the Ethics Committee of the participating hospital and the written informed consent was obtained from all subjects.

Study population

The study enrolled 83 patients of whom 79 patients were analysed. COPD was diagnosed according to GOLD criteria [9] based on pulmonary function tests. All patients were discussed in a multidisciplinary lung cancer expert board that includes chest physicians, oncologists, radiologists and thoracic surgeons. All patients with FEV1 or carbon monoxide diffusion capacity (DLCO) predicted postoperative <40% underwent CPET according to the locally accepted guidelines [5]. Those with no significant comorbidity and VO2 max of >10 ml/kg/min were considered as fit and underwent surgical treatment. Thoracotomy was the commonly used surgical approach for management. All the patients underwent postoperative respiratory rehabilitation according to the institutional protocol, including early mobilization and incentive spirometry with pain control and inhalation of bronchodilators and/or mucolytics. Postoperative cardiopulmonary complications and mortality were recorded during the 12 months after surgery (Fig. 1). We analysed the postoperative pulmonary complications—including bronchopleural fistula defined as persistent chest tube leak of >7 days, empyema, atelectasis, pneumonia, acute respiratory failure requiring >48 h ventilation, adult respiratory distress syndrome, haemothorax, chylothorax, subcutaneous emphysema, pulmonary oedema, pulmonary embolism, lobar torsion, cardiac hernia, oesophago-pleural fistula and new requirement for chronic oxygen therapy—and cardiac complications namely cardiac arrhythmias, acute myocardial infarction and acute coronary syndrome. Moreover, local tumour recurrence during the 12 months following the surgery was recorded.

Flow chart of studied patients.
Figure 1:

Flow chart of studied patients.

Characterization of participants

All patients underwent clinical history (including age, gender, associated cardiac comorbidities, smoking history) and pulmonary function testing [including forced spirometry, DLCO and its correction to alveolar volume (KCO) and static lung volumes] that was performed according to the international guidelines.

Cardiopulmonary exercise testing

All patients underwent CPET using an electromagnetically braked cycle ergometer (Ergocard, Medi-soft S.A., Belgium) according to the international guidelines [10]. Reference values were taken from Jones et al. [11]. Serial blood gases analyses were taken every 2 min throughout the test for lactate measurement. All the parameters of the test were recorded at baseline, anaerobic threshold (AT) and maximal work load.

Statistical analysis

All the data were expressed as mean ± standard deviation unless otherwise stated. Categorized variables were expressed as numbers and percentages. Comparisons between different groups were performed using the χ2 or unpaired t-test as appropriate. Univariable and multivariable cox regression hazard analysis was applied to study the survival dependency of different CPET parameters. Stepwise selection was used for multivariable model building. The choice of covariables was verified by hands-on modelling, where terms are added or removed in a logical order based on heavily clinically related covariables in combination with a review of the literature rather than solely according to the statistical significance to identify predictors for multivariable analyses. Multiple multivariable models were tried and the one showing best overall goodness-of-fit was chosen. Both the hazard ratio and 95% confidence interval (CI) were shown. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used to identify the sensitivity and specificity for selected CPET parameters in relation to associated events. Kaplan–Meier survival analysis was plotted to identify the survival probability. A two-tailed P-value <0.05 was considered statistically significant. MedCalc® (version 9.2.1.0, Acacialaan 22, B-8400 Ostend, Belgium) and SPSS package (version 18; Chicago, USA) were used for all analyses.

RESULTS

Study population

Twenty-four COPD patients were considered unfit for surgery and received an alternative therapy, whereas 55 patients had a predictive postoperative VO2 max of >10 ml/kg/min and underwent a lung surgery (Fig. 1). Seventy-two percent of the patients met the GOLD criteria of moderate to very severe airflow obstruction. There was no statistical difference between those fit and unfit for surgery, regarding the basal characteristics and pulmonary function test (P > 0.05) except for KCO% (P = 0.026; Supplementary Table S1). In 4 patients who underwent a surgery, the tumour was considered irresectable intraoperatively and no resection was performed. Fifty-one patients had a resection surgery. Eight patients (14.5%) underwent a pneumonectomy, 31 patients (56.4%) a lobectomy and 12 patients (21.8%) either a segmentectomy or atypical resection of pulmonary nodule. Among them, 4% died and 41% developed complications (Fig. 1). The postoperative complications were lung atelectasis (4 patients; 7.8%), atrial fibrillation (2 patients; 4%), pulmonary oedema (1 patient; 1.96%), postoperative pneumonia (2 patients; 4%), haemothorax (1 patient; 1.96%), subcutaneous emphysema (3 patients; 5.9%), acute respiratory failure (2 patients; 4%) and 17.6% (9 patients) required oxygen therapy postoperatively. During the follow-up of the studied population, we reported no recurrence of the local tumour. The clinical characteristics and functional parameters of the patients considered fit for surgery according to the development of postoperative complications or mortality are summarized in Table 1. Moreover, the clinical characteristics and functional parameters of those developed postoperative complications versus postoperative mortality are given in Supplementary Table S2.

Table 1:

Characteristics of patients who underwent lung resection according to the presence or absence of all postoperative events (complications and mortality)

Events
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Age (years)67.1 ± 7.064 ± 10.70.234
Gender (male/female); n (%)19 (82.6)/4 (17.4)23 (82.1)/5 (17.9)0.965
BMI28.9 ± 6.027.0 ± 4.00.195
Smoking history
 Current/former smokers/non-smoker; n (%)13 (56.5)/10 (43.5)15 (53.6)/12 (42.9)/1 (3.6)0.656
 Smoking index (pack/year)56.4 ± 28.955.36 ± 26.20.896
Presence of comorbidity
 Cardiac; n (%)13 (56.5)12 (42.9)0.395
 Others; n (%)10 (43.5)13 (46.4)0.833
Pulmonary function test
 FEV1/FVC (%)56.0 ± 14.9655.2 ± 12.220.844
 FEV1 (l)1.75 ± 0.641.8 ± 0.580.632
 FEV1%58.7 ± 18.261.1 ± 17.60.778
 FVC (l)3.19 ± 0.673.23 ± 0.610.828
 FVC%80.8 ± 11.883.8 ± 12.990.403
 DLCO%41.8 ± 9.553.8 ± 18.80.031
 KCO%46.5 ± 9.759.5 ± 19.20.026
Type of pathological tumour
 Adenocarcinoma14 (60.9)10 (35.7)0.541
 Squamous cell carcinoma7 (30.4)13 (46.4)
 Others2 (8.7)5 (17.9)
Staging
 Stage IA8 (34.8)11 (39.3)0.294
 Stage IIA/IIB6 (26.1)/7 (30.4)5 (17.9)/4 (14.3)
 Stage IIIA2 (8.7)7 (25)
 Stage IVa0 (0)1 (3.6)
Type of surgery
 Pneumonectomy1 (4.3)7 (25)0.103
 Lobectomy15 (65.2)16 (57.1)
 Segmentectomy/atypical surgery7 (30.4)5 (17.9)
Events
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Age (years)67.1 ± 7.064 ± 10.70.234
Gender (male/female); n (%)19 (82.6)/4 (17.4)23 (82.1)/5 (17.9)0.965
BMI28.9 ± 6.027.0 ± 4.00.195
Smoking history
 Current/former smokers/non-smoker; n (%)13 (56.5)/10 (43.5)15 (53.6)/12 (42.9)/1 (3.6)0.656
 Smoking index (pack/year)56.4 ± 28.955.36 ± 26.20.896
Presence of comorbidity
 Cardiac; n (%)13 (56.5)12 (42.9)0.395
 Others; n (%)10 (43.5)13 (46.4)0.833
Pulmonary function test
 FEV1/FVC (%)56.0 ± 14.9655.2 ± 12.220.844
 FEV1 (l)1.75 ± 0.641.8 ± 0.580.632
 FEV1%58.7 ± 18.261.1 ± 17.60.778
 FVC (l)3.19 ± 0.673.23 ± 0.610.828
 FVC%80.8 ± 11.883.8 ± 12.990.403
 DLCO%41.8 ± 9.553.8 ± 18.80.031
 KCO%46.5 ± 9.759.5 ± 19.20.026
Type of pathological tumour
 Adenocarcinoma14 (60.9)10 (35.7)0.541
 Squamous cell carcinoma7 (30.4)13 (46.4)
 Others2 (8.7)5 (17.9)
Staging
 Stage IA8 (34.8)11 (39.3)0.294
 Stage IIA/IIB6 (26.1)/7 (30.4)5 (17.9)/4 (14.3)
 Stage IIIA2 (8.7)7 (25)
 Stage IVa0 (0)1 (3.6)
Type of surgery
 Pneumonectomy1 (4.3)7 (25)0.103
 Lobectomy15 (65.2)16 (57.1)
 Segmentectomy/atypical surgery7 (30.4)5 (17.9)

DLCO: diffusing capacity for carbon monoxide; BMI: body mass index; FVC: forced vital capacity; KCO: carbon monoxide transfer coefficient.

aThis patient had solitary brain metastasis.

Table 1:

Characteristics of patients who underwent lung resection according to the presence or absence of all postoperative events (complications and mortality)

Events
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Age (years)67.1 ± 7.064 ± 10.70.234
Gender (male/female); n (%)19 (82.6)/4 (17.4)23 (82.1)/5 (17.9)0.965
BMI28.9 ± 6.027.0 ± 4.00.195
Smoking history
 Current/former smokers/non-smoker; n (%)13 (56.5)/10 (43.5)15 (53.6)/12 (42.9)/1 (3.6)0.656
 Smoking index (pack/year)56.4 ± 28.955.36 ± 26.20.896
Presence of comorbidity
 Cardiac; n (%)13 (56.5)12 (42.9)0.395
 Others; n (%)10 (43.5)13 (46.4)0.833
Pulmonary function test
 FEV1/FVC (%)56.0 ± 14.9655.2 ± 12.220.844
 FEV1 (l)1.75 ± 0.641.8 ± 0.580.632
 FEV1%58.7 ± 18.261.1 ± 17.60.778
 FVC (l)3.19 ± 0.673.23 ± 0.610.828
 FVC%80.8 ± 11.883.8 ± 12.990.403
 DLCO%41.8 ± 9.553.8 ± 18.80.031
 KCO%46.5 ± 9.759.5 ± 19.20.026
Type of pathological tumour
 Adenocarcinoma14 (60.9)10 (35.7)0.541
 Squamous cell carcinoma7 (30.4)13 (46.4)
 Others2 (8.7)5 (17.9)
Staging
 Stage IA8 (34.8)11 (39.3)0.294
 Stage IIA/IIB6 (26.1)/7 (30.4)5 (17.9)/4 (14.3)
 Stage IIIA2 (8.7)7 (25)
 Stage IVa0 (0)1 (3.6)
Type of surgery
 Pneumonectomy1 (4.3)7 (25)0.103
 Lobectomy15 (65.2)16 (57.1)
 Segmentectomy/atypical surgery7 (30.4)5 (17.9)
Events
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Age (years)67.1 ± 7.064 ± 10.70.234
Gender (male/female); n (%)19 (82.6)/4 (17.4)23 (82.1)/5 (17.9)0.965
BMI28.9 ± 6.027.0 ± 4.00.195
Smoking history
 Current/former smokers/non-smoker; n (%)13 (56.5)/10 (43.5)15 (53.6)/12 (42.9)/1 (3.6)0.656
 Smoking index (pack/year)56.4 ± 28.955.36 ± 26.20.896
Presence of comorbidity
 Cardiac; n (%)13 (56.5)12 (42.9)0.395
 Others; n (%)10 (43.5)13 (46.4)0.833
Pulmonary function test
 FEV1/FVC (%)56.0 ± 14.9655.2 ± 12.220.844
 FEV1 (l)1.75 ± 0.641.8 ± 0.580.632
 FEV1%58.7 ± 18.261.1 ± 17.60.778
 FVC (l)3.19 ± 0.673.23 ± 0.610.828
 FVC%80.8 ± 11.883.8 ± 12.990.403
 DLCO%41.8 ± 9.553.8 ± 18.80.031
 KCO%46.5 ± 9.759.5 ± 19.20.026
Type of pathological tumour
 Adenocarcinoma14 (60.9)10 (35.7)0.541
 Squamous cell carcinoma7 (30.4)13 (46.4)
 Others2 (8.7)5 (17.9)
Staging
 Stage IA8 (34.8)11 (39.3)0.294
 Stage IIA/IIB6 (26.1)/7 (30.4)5 (17.9)/4 (14.3)
 Stage IIIA2 (8.7)7 (25)
 Stage IVa0 (0)1 (3.6)
Type of surgery
 Pneumonectomy1 (4.3)7 (25)0.103
 Lobectomy15 (65.2)16 (57.1)
 Segmentectomy/atypical surgery7 (30.4)5 (17.9)

DLCO: diffusing capacity for carbon monoxide; BMI: body mass index; FVC: forced vital capacity; KCO: carbon monoxide transfer coefficient.

aThis patient had solitary brain metastasis.

Cardiopulmonary exercise testing and pulmonary function test

The different CPET parameters of the studied cohort, both at baseline and at maximum exercise, are provided in Supplementary Table S3. Patients considered fit for surgery had higher heart rate and systolic blood pressure at maximal exercise and achieved higher work load, higher minute ventilation, higher oxygen uptake and carbon dioxide (CO2) output at maximum exercise as well as higher lactic acid than unfit patients. At the point of AT, there was no significant difference in the studied parameters, other than VO2/kg (10.79 ± 2.7 vs 8.96 ± 1.7 ml/kg/min, P = 0.003, Supplementary Table S3).

Moreover, there was no statistical significant difference when comparing the different CPET parameters at maximal exercise or AT among those who underwent surgical lung resection, i.e. 51 patients (Fig. 1) regarding the presence or absence of overall events including postoperative complications and mortality (Table 2). However, patients who developed complications or died postoperatively had higher VE/VCO2 at baseline (51.3 ± 8.4 vs 46.4 ± 8.6, P = 0.047; Table 2) and lower diffusing capacity (P = 0.031 and 0.026 for DLCO% and KCO%, respectively; Table 1). Furthermore, patients who died postoperatively had statistically significant higher systolic blood pressure at maximal exercise (P < 0.001; Supplementary Table S4), but no significant differences regarding the other CPET parameters or pulmonary function (Supplementary Tables S3 and S4).

Table 2:

Cardiopulmonary exercise testing parameters regarding the development of all postoperative events (complications and mortality)

ParameterEvents
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Baseline
 VE (l/min)13.4 ± 4.112.1 ± 2.80.219
 VE%24.7 ± 13.921.4 ± 10.70.338
 VO2 (l/min)0.3 ± 0.110.29 ± 0.080.755
 VO2%20.03 ± 6.518.5 ± 5.40.375
 VO2/kg (ml/kg/min)4.43 ± 1.553.99 ± 1.120.268
 VO2/kg%19.6 ± 5.818.3 ± 4.90.373
 VCO2 (l/min)0.28 ± 0.10.27 ± 0.070.722
 Respiratory rate (breath/min)20.7 ± 7.617.5 ± 5.80.098
 RQ0.89 ± 0.090.91 ± 0.090.534
 Heart rate (b/min)77.9 ± 14.578.9 ± 11.60.780
 Heart rate%50.97 ± 9.750.9 ± 7.70.969
 Lactic acid (mEq/l)1.51 ± 0.581.65 ± 0.890.554
 Systolic blood pressure (mmHg)144 ± 19.12136.9 ± 21.970.246
 Diastolic blood pressure (mmHg)77.43 ± 10.479.2 ± 15.50.651
 VE/VCO251.3 ± 8.446.4 ± 8.60.047
 VO2/HR (ml/beat)3.9 ± 1.33.8 ± 1.30.650
 VO2/HR%40.02 ± 13.636.5 ± 12.50.345
 PETCO2 (mmHg)30.8 ± 3.733.01 ± 4.40.062
Maximum exercise
 Time (min)11.5 ± 2.311.3 ± 2.50.735
 Work load (watts)77.7 ± 21.878.9 ± 26.70.857
 Work load%73.2 ± 20.869.3 ± 17.90.444
 VE (l/min)56.9 ± 13.155.1 ± 11.50.617
 VE%95.9 ± 25.489.4 ± 21.30.323
 VO2 (l/min)1.14 ± 0.261.23 ± 0.360.312
 VO2%76.2 ± 19.275.7 ± 15.60.794
 VO2/kg (ml/kg/min)16.7 ± 3.616.5 ± 3.90.872
 VO2/kg%75.1 ± 20.674.8 ± 16.50.948
 VCO2 (l/min)1.41 ± 0.311.47 ± 0.420.562
 Respiratory rate (br/min)36.7 ± 7.136.8 ± 9.030.986
 RQ1.24 ± 0.171.21 ± 0.130.424
 Heart rate (b/min)132.6 ± 14.7130.5 ± 22.60.702
 Heart rate%86.8 ± 9.683.9 ± 12.70.374
 Lactic acid (mEq/l)5.4 ± 2.24.9 ± 1.30.433
 Systolic blood pressure (mmHg)210.6 ± 28.4200.1 ± 26.60.195
 Diastolic blood pressure (mmHg)92.2 ± 14.394.9 ± 15.040.527
 VE/VCO240.8 ± 6.138.8 ± 8.70.366
 VO2/HR (ml/beat)8.7 ± 1.89.5 ± 2.30.175
 VO2/HR%88.9 ± 20.490.1 ± 15.50.821
 PETCO2 (mmHg)32.4 ± 5.0433.8 ± 5.90.362
ParameterEvents
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Baseline
 VE (l/min)13.4 ± 4.112.1 ± 2.80.219
 VE%24.7 ± 13.921.4 ± 10.70.338
 VO2 (l/min)0.3 ± 0.110.29 ± 0.080.755
 VO2%20.03 ± 6.518.5 ± 5.40.375
 VO2/kg (ml/kg/min)4.43 ± 1.553.99 ± 1.120.268
 VO2/kg%19.6 ± 5.818.3 ± 4.90.373
 VCO2 (l/min)0.28 ± 0.10.27 ± 0.070.722
 Respiratory rate (breath/min)20.7 ± 7.617.5 ± 5.80.098
 RQ0.89 ± 0.090.91 ± 0.090.534
 Heart rate (b/min)77.9 ± 14.578.9 ± 11.60.780
 Heart rate%50.97 ± 9.750.9 ± 7.70.969
 Lactic acid (mEq/l)1.51 ± 0.581.65 ± 0.890.554
 Systolic blood pressure (mmHg)144 ± 19.12136.9 ± 21.970.246
 Diastolic blood pressure (mmHg)77.43 ± 10.479.2 ± 15.50.651
 VE/VCO251.3 ± 8.446.4 ± 8.60.047
 VO2/HR (ml/beat)3.9 ± 1.33.8 ± 1.30.650
 VO2/HR%40.02 ± 13.636.5 ± 12.50.345
 PETCO2 (mmHg)30.8 ± 3.733.01 ± 4.40.062
Maximum exercise
 Time (min)11.5 ± 2.311.3 ± 2.50.735
 Work load (watts)77.7 ± 21.878.9 ± 26.70.857
 Work load%73.2 ± 20.869.3 ± 17.90.444
 VE (l/min)56.9 ± 13.155.1 ± 11.50.617
 VE%95.9 ± 25.489.4 ± 21.30.323
 VO2 (l/min)1.14 ± 0.261.23 ± 0.360.312
 VO2%76.2 ± 19.275.7 ± 15.60.794
 VO2/kg (ml/kg/min)16.7 ± 3.616.5 ± 3.90.872
 VO2/kg%75.1 ± 20.674.8 ± 16.50.948
 VCO2 (l/min)1.41 ± 0.311.47 ± 0.420.562
 Respiratory rate (br/min)36.7 ± 7.136.8 ± 9.030.986
 RQ1.24 ± 0.171.21 ± 0.130.424
 Heart rate (b/min)132.6 ± 14.7130.5 ± 22.60.702
 Heart rate%86.8 ± 9.683.9 ± 12.70.374
 Lactic acid (mEq/l)5.4 ± 2.24.9 ± 1.30.433
 Systolic blood pressure (mmHg)210.6 ± 28.4200.1 ± 26.60.195
 Diastolic blood pressure (mmHg)92.2 ± 14.394.9 ± 15.040.527
 VE/VCO240.8 ± 6.138.8 ± 8.70.366
 VO2/HR (ml/beat)8.7 ± 1.89.5 ± 2.30.175
 VO2/HR%88.9 ± 20.490.1 ± 15.50.821
 PETCO2 (mmHg)32.4 ± 5.0433.8 ± 5.90.362

br/min: breath/minute; VE: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide output; RQ: respiratory quotient; HR: heart rate; VO2/HR: oxygen pulse; PETCO2: end-tidal carbon dioxide pressure.

Table 2:

Cardiopulmonary exercise testing parameters regarding the development of all postoperative events (complications and mortality)

ParameterEvents
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Baseline
 VE (l/min)13.4 ± 4.112.1 ± 2.80.219
 VE%24.7 ± 13.921.4 ± 10.70.338
 VO2 (l/min)0.3 ± 0.110.29 ± 0.080.755
 VO2%20.03 ± 6.518.5 ± 5.40.375
 VO2/kg (ml/kg/min)4.43 ± 1.553.99 ± 1.120.268
 VO2/kg%19.6 ± 5.818.3 ± 4.90.373
 VCO2 (l/min)0.28 ± 0.10.27 ± 0.070.722
 Respiratory rate (breath/min)20.7 ± 7.617.5 ± 5.80.098
 RQ0.89 ± 0.090.91 ± 0.090.534
 Heart rate (b/min)77.9 ± 14.578.9 ± 11.60.780
 Heart rate%50.97 ± 9.750.9 ± 7.70.969
 Lactic acid (mEq/l)1.51 ± 0.581.65 ± 0.890.554
 Systolic blood pressure (mmHg)144 ± 19.12136.9 ± 21.970.246
 Diastolic blood pressure (mmHg)77.43 ± 10.479.2 ± 15.50.651
 VE/VCO251.3 ± 8.446.4 ± 8.60.047
 VO2/HR (ml/beat)3.9 ± 1.33.8 ± 1.30.650
 VO2/HR%40.02 ± 13.636.5 ± 12.50.345
 PETCO2 (mmHg)30.8 ± 3.733.01 ± 4.40.062
Maximum exercise
 Time (min)11.5 ± 2.311.3 ± 2.50.735
 Work load (watts)77.7 ± 21.878.9 ± 26.70.857
 Work load%73.2 ± 20.869.3 ± 17.90.444
 VE (l/min)56.9 ± 13.155.1 ± 11.50.617
 VE%95.9 ± 25.489.4 ± 21.30.323
 VO2 (l/min)1.14 ± 0.261.23 ± 0.360.312
 VO2%76.2 ± 19.275.7 ± 15.60.794
 VO2/kg (ml/kg/min)16.7 ± 3.616.5 ± 3.90.872
 VO2/kg%75.1 ± 20.674.8 ± 16.50.948
 VCO2 (l/min)1.41 ± 0.311.47 ± 0.420.562
 Respiratory rate (br/min)36.7 ± 7.136.8 ± 9.030.986
 RQ1.24 ± 0.171.21 ± 0.130.424
 Heart rate (b/min)132.6 ± 14.7130.5 ± 22.60.702
 Heart rate%86.8 ± 9.683.9 ± 12.70.374
 Lactic acid (mEq/l)5.4 ± 2.24.9 ± 1.30.433
 Systolic blood pressure (mmHg)210.6 ± 28.4200.1 ± 26.60.195
 Diastolic blood pressure (mmHg)92.2 ± 14.394.9 ± 15.040.527
 VE/VCO240.8 ± 6.138.8 ± 8.70.366
 VO2/HR (ml/beat)8.7 ± 1.89.5 ± 2.30.175
 VO2/HR%88.9 ± 20.490.1 ± 15.50.821
 PETCO2 (mmHg)32.4 ± 5.0433.8 ± 5.90.362
ParameterEvents
Significance (P-value)
Yes (n = 23; 45%)No (n = 28; 55%)
Baseline
 VE (l/min)13.4 ± 4.112.1 ± 2.80.219
 VE%24.7 ± 13.921.4 ± 10.70.338
 VO2 (l/min)0.3 ± 0.110.29 ± 0.080.755
 VO2%20.03 ± 6.518.5 ± 5.40.375
 VO2/kg (ml/kg/min)4.43 ± 1.553.99 ± 1.120.268
 VO2/kg%19.6 ± 5.818.3 ± 4.90.373
 VCO2 (l/min)0.28 ± 0.10.27 ± 0.070.722
 Respiratory rate (breath/min)20.7 ± 7.617.5 ± 5.80.098
 RQ0.89 ± 0.090.91 ± 0.090.534
 Heart rate (b/min)77.9 ± 14.578.9 ± 11.60.780
 Heart rate%50.97 ± 9.750.9 ± 7.70.969
 Lactic acid (mEq/l)1.51 ± 0.581.65 ± 0.890.554
 Systolic blood pressure (mmHg)144 ± 19.12136.9 ± 21.970.246
 Diastolic blood pressure (mmHg)77.43 ± 10.479.2 ± 15.50.651
 VE/VCO251.3 ± 8.446.4 ± 8.60.047
 VO2/HR (ml/beat)3.9 ± 1.33.8 ± 1.30.650
 VO2/HR%40.02 ± 13.636.5 ± 12.50.345
 PETCO2 (mmHg)30.8 ± 3.733.01 ± 4.40.062
Maximum exercise
 Time (min)11.5 ± 2.311.3 ± 2.50.735
 Work load (watts)77.7 ± 21.878.9 ± 26.70.857
 Work load%73.2 ± 20.869.3 ± 17.90.444
 VE (l/min)56.9 ± 13.155.1 ± 11.50.617
 VE%95.9 ± 25.489.4 ± 21.30.323
 VO2 (l/min)1.14 ± 0.261.23 ± 0.360.312
 VO2%76.2 ± 19.275.7 ± 15.60.794
 VO2/kg (ml/kg/min)16.7 ± 3.616.5 ± 3.90.872
 VO2/kg%75.1 ± 20.674.8 ± 16.50.948
 VCO2 (l/min)1.41 ± 0.311.47 ± 0.420.562
 Respiratory rate (br/min)36.7 ± 7.136.8 ± 9.030.986
 RQ1.24 ± 0.171.21 ± 0.130.424
 Heart rate (b/min)132.6 ± 14.7130.5 ± 22.60.702
 Heart rate%86.8 ± 9.683.9 ± 12.70.374
 Lactic acid (mEq/l)5.4 ± 2.24.9 ± 1.30.433
 Systolic blood pressure (mmHg)210.6 ± 28.4200.1 ± 26.60.195
 Diastolic blood pressure (mmHg)92.2 ± 14.394.9 ± 15.040.527
 VE/VCO240.8 ± 6.138.8 ± 8.70.366
 VO2/HR (ml/beat)8.7 ± 1.89.5 ± 2.30.175
 VO2/HR%88.9 ± 20.490.1 ± 15.50.821
 PETCO2 (mmHg)32.4 ± 5.0433.8 ± 5.90.362

br/min: breath/minute; VE: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide output; RQ: respiratory quotient; HR: heart rate; VO2/HR: oxygen pulse; PETCO2: end-tidal carbon dioxide pressure.

Regression models

Cox proportional hazards regression analysis showed that baseline VE/VCO2 slope was the only CPET parameter associated with postoperative complications, with a hazard ratio of 2.6 (P = 0.008; Table 3). In addition, percentage of predicted minute ventilation (VE%), VCO2 (l/min), percentage of VO2 max (VO2/kg) and respiratory quotient (RQ) were the best single predictors of overall events including both postoperative complications and mortality (P < 0.05; Table 3). Thirty-seven patients (72.2%) of the patients considered fit for surgery had VE/VCO2 slope at maximal exercise of >35. VE/VCO2 slope at maximal exercise of >35 had the best sensitivity and negative predictive value of (82.6 and 78%, respectively) in predicting postoperative complications analysed by ROC (AUC = 0.634, CI 95% = 0.487–0.764, P = 0.092). VE/VCO2 slope of >35 was the parameter most strongly associated with the probability of mortality or postoperative complications in patients with VO2/kg higher than 10 ml/kg/min (hazard ratio 5.14), and was also associated with a survival probability of 30% after 1-year follow-up (Fig. 2). Furthermore, VE/VCO2 slope of >35 was still significant in the multivariable analysis (P = 0.017; Table 4); similarly, work load (watts) and VO2 (l/min) at maximal exercise have a statistical significance in the multivariable analysis. Moreover, VO2 (l/min) was a significant protector factor (P = 0.036; Table 4) that was not present in the univariable analysis (P = 0.132; Table 3). Kaplan–Meier survival analysis for the presence of complications in the multivariable model was 40% for all covariates after 1-year follow-up (Fig. 3). However, 1-year survival of the high-risk surgical patients (i.e. those with VE/VCO2 slope of >35) did not significantly differ from those who underwent non-surgical treatment for their lung cancer (P = 0.148; Fig. 4). Among the patients who underwent lung resection, 37% (19 patients) had poor 1-year survival secondary to their cancer stage, whereas 45% (23 patients) had poor 1-year survival due to poor pulmonary function and high VE/VCO2 slope of >35.

Table 3:

Univariable Cox proportional hazards regression analysis of different clinical and CPET parameters regarding the overall postoperative events

BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Clinical parameters
 Gender−0.3310.4950.5040.7180.2721.896
 Age0.1010.2530.6881.1070.6741.817
 Smoking index−0.0040.1650.9820.9960.7211.377
 Non-cardiac comorbidity1.1921.0270.2463.2940.44024.631
 Cardiac comorbidities−0.3810.4950.4410.6830.2591.802
 Staging of lung cancer0.0060.0290.8301.0060.9501.066
 Type of operation0.1080.3640.7661.1140.5462.276
 VE/VCO2 at baseline0.9730.3680.0082.6451.2865.438
At AT
 Work load AT0.2530.2480.3091.2870.7912.095
 Work load% AT−0.0570.2480.8190.9450.5811.537
 VE (l) AT0.4640.3210.1481.5910.8482.983
 VE% AT0.6180.2740.0241.8561.0853.176
 VO2 (l) AT−0.4150.3280.2070.6610.3471.257
 VO2% AT−0.2250.2850.4300.7980.4571.396
 VO2/kg AT0.0550.2410.8191.0570.6591.695
 VO2/kg% AT−0.0970.2870.7350.9070.5171.592
 VCO2 (l) AT−0.1910.3000.5230.8260.4591.487
 RR AT−0.0980.3020.7460.9070.5021.638
 RQ AT0.5900.3200.0651.8030.9633.377
 HR AT−0.2690.2690.3180.7640.4511.295
 HR% AT−0.2040.2310.3770.8160.5191.282
 Lactic acid AT0.1540.3040.6121.1670.6432.117
 Systolic BP AT−0.1050.2850.7130.9010.5151.574
 Diastolic BP AT−0.0300.2510.9050.9700.5931.588
 VE/VCO2 AT0.5130.3760.1731.6700.7993.487
 VO2/HR AT−0.0210.2250.9250.9790.6301.522
 VO2/HR% AT0.0650.2170.7641.0670.6981.633
 PETCO2 AT−0.5560.2700.0390.5730.3380.973
At maximal exercise
 Work load max0.0230.2070.9131.0230.6811.535
 Work load% max−0.0130.2700.9610.9870.5821.674
 VE (l) max0.2180.2520.3851.2440.7602.037
 VE% max0.4800.2370.0431.6161.0162.571
 VO2 (l) max−0.3110.2070.1320.7330.4881.099
 VO2% max−0.2610.2020.1950.7700.5181.144
 VO2/kg max−0.3960.2470.1090.6730.4151.093
 VO2/kg% max−0.5180.2520.0400.5960.3630.976
 VCO2 (l) max0.3520.2280.1231.4210.9092.223
 RR max−0.0370.1990.8520.9630.6521.423
 RQ max0.4380.2220.0491.5491.0022.396
 HR max−0.1870.2570.4660.8290.5011.372
 HR% max−0.3250.2020.1070.7220.4861.073
 Lactic acid max0.0900.2610.7291.0950.6561.825
 Systolic BP max0.2580.2510.3041.2950.7912.120
 Diastolic BP max0.0530.1920.7821.0550.7231.538
 VE/VCO2 max0.4070.3240.2091.5020.7962.838
 VO2/HR max−0.1440.2270.5260.8660.5541.352
 VO2/HR% max−0.2490.2350.2890.7790.4921.235
 PETCO2 max−0.3350.2420.1660.7150.4451.149
 VE/VCO2 max of >351.6380.6570.0135.1441.41818.660
BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Clinical parameters
 Gender−0.3310.4950.5040.7180.2721.896
 Age0.1010.2530.6881.1070.6741.817
 Smoking index−0.0040.1650.9820.9960.7211.377
 Non-cardiac comorbidity1.1921.0270.2463.2940.44024.631
 Cardiac comorbidities−0.3810.4950.4410.6830.2591.802
 Staging of lung cancer0.0060.0290.8301.0060.9501.066
 Type of operation0.1080.3640.7661.1140.5462.276
 VE/VCO2 at baseline0.9730.3680.0082.6451.2865.438
At AT
 Work load AT0.2530.2480.3091.2870.7912.095
 Work load% AT−0.0570.2480.8190.9450.5811.537
 VE (l) AT0.4640.3210.1481.5910.8482.983
 VE% AT0.6180.2740.0241.8561.0853.176
 VO2 (l) AT−0.4150.3280.2070.6610.3471.257
 VO2% AT−0.2250.2850.4300.7980.4571.396
 VO2/kg AT0.0550.2410.8191.0570.6591.695
 VO2/kg% AT−0.0970.2870.7350.9070.5171.592
 VCO2 (l) AT−0.1910.3000.5230.8260.4591.487
 RR AT−0.0980.3020.7460.9070.5021.638
 RQ AT0.5900.3200.0651.8030.9633.377
 HR AT−0.2690.2690.3180.7640.4511.295
 HR% AT−0.2040.2310.3770.8160.5191.282
 Lactic acid AT0.1540.3040.6121.1670.6432.117
 Systolic BP AT−0.1050.2850.7130.9010.5151.574
 Diastolic BP AT−0.0300.2510.9050.9700.5931.588
 VE/VCO2 AT0.5130.3760.1731.6700.7993.487
 VO2/HR AT−0.0210.2250.9250.9790.6301.522
 VO2/HR% AT0.0650.2170.7641.0670.6981.633
 PETCO2 AT−0.5560.2700.0390.5730.3380.973
At maximal exercise
 Work load max0.0230.2070.9131.0230.6811.535
 Work load% max−0.0130.2700.9610.9870.5821.674
 VE (l) max0.2180.2520.3851.2440.7602.037
 VE% max0.4800.2370.0431.6161.0162.571
 VO2 (l) max−0.3110.2070.1320.7330.4881.099
 VO2% max−0.2610.2020.1950.7700.5181.144
 VO2/kg max−0.3960.2470.1090.6730.4151.093
 VO2/kg% max−0.5180.2520.0400.5960.3630.976
 VCO2 (l) max0.3520.2280.1231.4210.9092.223
 RR max−0.0370.1990.8520.9630.6521.423
 RQ max0.4380.2220.0491.5491.0022.396
 HR max−0.1870.2570.4660.8290.5011.372
 HR% max−0.3250.2020.1070.7220.4861.073
 Lactic acid max0.0900.2610.7291.0950.6561.825
 Systolic BP max0.2580.2510.3041.2950.7912.120
 Diastolic BP max0.0530.1920.7821.0550.7231.538
 VE/VCO2 max0.4070.3240.2091.5020.7962.838
 VO2/HR max−0.1440.2270.5260.8660.5541.352
 VO2/HR% max−0.2490.2350.2890.7790.4921.235
 PETCO2 max−0.3350.2420.1660.7150.4451.149
 VE/VCO2 max of >351.6380.6570.0135.1441.41818.660

CPET: cardiopulmonary exercise testing; CI: confidence interval; AT: anaerobic threshold; VE: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide output; RQ: respiratory quotient; HR: heart rate; PETCO2: end-tidal carbon dioxide pressure; SE: standard error; RR: respiratory rate; BP: blood pressure.

Table 3:

Univariable Cox proportional hazards regression analysis of different clinical and CPET parameters regarding the overall postoperative events

BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Clinical parameters
 Gender−0.3310.4950.5040.7180.2721.896
 Age0.1010.2530.6881.1070.6741.817
 Smoking index−0.0040.1650.9820.9960.7211.377
 Non-cardiac comorbidity1.1921.0270.2463.2940.44024.631
 Cardiac comorbidities−0.3810.4950.4410.6830.2591.802
 Staging of lung cancer0.0060.0290.8301.0060.9501.066
 Type of operation0.1080.3640.7661.1140.5462.276
 VE/VCO2 at baseline0.9730.3680.0082.6451.2865.438
At AT
 Work load AT0.2530.2480.3091.2870.7912.095
 Work load% AT−0.0570.2480.8190.9450.5811.537
 VE (l) AT0.4640.3210.1481.5910.8482.983
 VE% AT0.6180.2740.0241.8561.0853.176
 VO2 (l) AT−0.4150.3280.2070.6610.3471.257
 VO2% AT−0.2250.2850.4300.7980.4571.396
 VO2/kg AT0.0550.2410.8191.0570.6591.695
 VO2/kg% AT−0.0970.2870.7350.9070.5171.592
 VCO2 (l) AT−0.1910.3000.5230.8260.4591.487
 RR AT−0.0980.3020.7460.9070.5021.638
 RQ AT0.5900.3200.0651.8030.9633.377
 HR AT−0.2690.2690.3180.7640.4511.295
 HR% AT−0.2040.2310.3770.8160.5191.282
 Lactic acid AT0.1540.3040.6121.1670.6432.117
 Systolic BP AT−0.1050.2850.7130.9010.5151.574
 Diastolic BP AT−0.0300.2510.9050.9700.5931.588
 VE/VCO2 AT0.5130.3760.1731.6700.7993.487
 VO2/HR AT−0.0210.2250.9250.9790.6301.522
 VO2/HR% AT0.0650.2170.7641.0670.6981.633
 PETCO2 AT−0.5560.2700.0390.5730.3380.973
At maximal exercise
 Work load max0.0230.2070.9131.0230.6811.535
 Work load% max−0.0130.2700.9610.9870.5821.674
 VE (l) max0.2180.2520.3851.2440.7602.037
 VE% max0.4800.2370.0431.6161.0162.571
 VO2 (l) max−0.3110.2070.1320.7330.4881.099
 VO2% max−0.2610.2020.1950.7700.5181.144
 VO2/kg max−0.3960.2470.1090.6730.4151.093
 VO2/kg% max−0.5180.2520.0400.5960.3630.976
 VCO2 (l) max0.3520.2280.1231.4210.9092.223
 RR max−0.0370.1990.8520.9630.6521.423
 RQ max0.4380.2220.0491.5491.0022.396
 HR max−0.1870.2570.4660.8290.5011.372
 HR% max−0.3250.2020.1070.7220.4861.073
 Lactic acid max0.0900.2610.7291.0950.6561.825
 Systolic BP max0.2580.2510.3041.2950.7912.120
 Diastolic BP max0.0530.1920.7821.0550.7231.538
 VE/VCO2 max0.4070.3240.2091.5020.7962.838
 VO2/HR max−0.1440.2270.5260.8660.5541.352
 VO2/HR% max−0.2490.2350.2890.7790.4921.235
 PETCO2 max−0.3350.2420.1660.7150.4451.149
 VE/VCO2 max of >351.6380.6570.0135.1441.41818.660
BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Clinical parameters
 Gender−0.3310.4950.5040.7180.2721.896
 Age0.1010.2530.6881.1070.6741.817
 Smoking index−0.0040.1650.9820.9960.7211.377
 Non-cardiac comorbidity1.1921.0270.2463.2940.44024.631
 Cardiac comorbidities−0.3810.4950.4410.6830.2591.802
 Staging of lung cancer0.0060.0290.8301.0060.9501.066
 Type of operation0.1080.3640.7661.1140.5462.276
 VE/VCO2 at baseline0.9730.3680.0082.6451.2865.438
At AT
 Work load AT0.2530.2480.3091.2870.7912.095
 Work load% AT−0.0570.2480.8190.9450.5811.537
 VE (l) AT0.4640.3210.1481.5910.8482.983
 VE% AT0.6180.2740.0241.8561.0853.176
 VO2 (l) AT−0.4150.3280.2070.6610.3471.257
 VO2% AT−0.2250.2850.4300.7980.4571.396
 VO2/kg AT0.0550.2410.8191.0570.6591.695
 VO2/kg% AT−0.0970.2870.7350.9070.5171.592
 VCO2 (l) AT−0.1910.3000.5230.8260.4591.487
 RR AT−0.0980.3020.7460.9070.5021.638
 RQ AT0.5900.3200.0651.8030.9633.377
 HR AT−0.2690.2690.3180.7640.4511.295
 HR% AT−0.2040.2310.3770.8160.5191.282
 Lactic acid AT0.1540.3040.6121.1670.6432.117
 Systolic BP AT−0.1050.2850.7130.9010.5151.574
 Diastolic BP AT−0.0300.2510.9050.9700.5931.588
 VE/VCO2 AT0.5130.3760.1731.6700.7993.487
 VO2/HR AT−0.0210.2250.9250.9790.6301.522
 VO2/HR% AT0.0650.2170.7641.0670.6981.633
 PETCO2 AT−0.5560.2700.0390.5730.3380.973
At maximal exercise
 Work load max0.0230.2070.9131.0230.6811.535
 Work load% max−0.0130.2700.9610.9870.5821.674
 VE (l) max0.2180.2520.3851.2440.7602.037
 VE% max0.4800.2370.0431.6161.0162.571
 VO2 (l) max−0.3110.2070.1320.7330.4881.099
 VO2% max−0.2610.2020.1950.7700.5181.144
 VO2/kg max−0.3960.2470.1090.6730.4151.093
 VO2/kg% max−0.5180.2520.0400.5960.3630.976
 VCO2 (l) max0.3520.2280.1231.4210.9092.223
 RR max−0.0370.1990.8520.9630.6521.423
 RQ max0.4380.2220.0491.5491.0022.396
 HR max−0.1870.2570.4660.8290.5011.372
 HR% max−0.3250.2020.1070.7220.4861.073
 Lactic acid max0.0900.2610.7291.0950.6561.825
 Systolic BP max0.2580.2510.3041.2950.7912.120
 Diastolic BP max0.0530.1920.7821.0550.7231.538
 VE/VCO2 max0.4070.3240.2091.5020.7962.838
 VO2/HR max−0.1440.2270.5260.8660.5541.352
 VO2/HR% max−0.2490.2350.2890.7790.4921.235
 PETCO2 max−0.3350.2420.1660.7150.4451.149
 VE/VCO2 max of >351.6380.6570.0135.1441.41818.660

CPET: cardiopulmonary exercise testing; CI: confidence interval; AT: anaerobic threshold; VE: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide output; RQ: respiratory quotient; HR: heart rate; PETCO2: end-tidal carbon dioxide pressure; SE: standard error; RR: respiratory rate; BP: blood pressure.

Table 4:

Multivariable Cox proportional hazards regression model regarding the overall events

Covariate (maximum exercise)BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Work load0.7740.3800.0422.1691.0294.570
VO2 (l)−0.7280.3470.0360.4830.2440.954
VE/VCO2 >35
Overall model
1.6670.6980.017
0.012
5.2961.34820.813
Covariate (maximum exercise)BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Work load0.7740.3800.0422.1691.0294.570
VO2 (l)−0.7280.3470.0360.4830.2440.954
VE/VCO2 >35
Overall model
1.6670.6980.017
0.012
5.2961.34820.813

CI: confidence interval; VO2: oxygen consumption; VCO2: carbon dioxide output.

Table 4:

Multivariable Cox proportional hazards regression model regarding the overall events

Covariate (maximum exercise)BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Work load0.7740.3800.0422.1691.0294.570
VO2 (l)−0.7280.3470.0360.4830.2440.954
VE/VCO2 >35
Overall model
1.6670.6980.017
0.012
5.2961.34820.813
Covariate (maximum exercise)BSESig.Hazard ratio95% CI for hazard ratio
LowerUpper
Work load0.7740.3800.0422.1691.0294.570
VO2 (l)−0.7280.3470.0360.4830.2440.954
VE/VCO2 >35
Overall model
1.6670.6980.017
0.012
5.2961.34820.813

CI: confidence interval; VO2: oxygen consumption; VCO2: carbon dioxide output.

Kaplan–Meier survival analysis for VE/VCO2 slope of >35. VE/VCO2: ventilation to carbon dioxide output.
Figure 2:

Kaplan–Meier survival analysis for VE/VCO2 slope of >35. VE/VCO2: ventilation to carbon dioxide output.

Kaplan–Meier survival analysis for the mean of multiple covariates at maximal exercise.
Figure 3:

Kaplan–Meier survival analysis for the mean of multiple covariates at maximal exercise.

Kaplan–Meier survival analysis comparing those who underwent non-surgical treatment of their lung cancer and the high-risk surgical patients (i.e. those with VE/VCO2 slope of >35).
Figure 4:

Kaplan–Meier survival analysis comparing those who underwent non-surgical treatment of their lung cancer and the high-risk surgical patients (i.e. those with VE/VCO2 slope of >35).

DISCUSSION

We have shown that COPD patients undergoing lung resection surgery for lung cancer are still at risk of complications and death despite preoperatively selecting the fitter patients. By analysing the functional parameters obtained during preoperative CPET, we have found that, even in those with VO2 max higher than 10 ml/kg/min, parameters of ventilator inefficiency, especially a VE/VCO2 slope of more than 35, are the strongest predictors of complications and death 1 year after surgery.

Previous studies and interpretation of the findings

We found that 41% developed postoperative cardiopulmonary complications, whereas 4% died despite being at an acceptable risk according to CPET. In accordance with our finding, Stanzani et al. [12] reported 31.6% morbidity and 4.3% mortality in their population subjected to CPET that correlated significantly with COPD. We observed that decreased diffusion capacity was related to postoperative complications and mortality. Similarly, Ferguson et al. [13] found that diminished diffusion capacity was associated with both mortality and pulmonary morbidity. We also observed that VO2/kg (ml/kg/min) at maximal exercise was not independently related to postoperative complications. Similarly, Campione et al. [14] did not find that measured VO2 max correlated with postoperative complications. In our population of COPD patients with VO2 max of >10 ml/kg/min, other factors may play an important role in the preoperative evaluation that are important to predict postoperative complications.

In this study, we found that the baseline VE/VCO2 slope was significantly higher among the patients who developed complications or died postoperatively with a hazard ratio of 2.6. Ventilatory inefficiency is one of the most important parameters that gained high acceptance in the evaluation of different groups of patients with problems such as COPD, interstitial lung diseases, pulmonary hypertension and congestive heart failure (CHF) [15]. Moreover, we found that VE% predicted at submaximal exercise (AT) and VE% predicted at maximal exercise were good predictors of all postoperative events as well as maximum VO2/kg (%) in the univariable analysis (Table 3) and VO2 (l/min) in the multivariable analysis (Table 4). This could be explained by the associated dynamic hyperinflation, an important pathophysiological characteristic of COPD, that increases during exercise and greatly compromises maximal exercise capacity reflected by lower VO2 max, VCO2 max and VE max [16]. Additionally, we found that higher RQ (reflecting combined VO2 and VCO2 changes) was another predictor of all postoperative events. It is accepted that VE is closely linked to both VO2 and VCO2 and more affected with the changes in VCO2 in a linear relationship and expressed as VE/VCO2.

Furthermore, we observed that VE/VCO2 slope of >35 was associated with all postoperative events in COPD patients. It has been previously demonstrated that VE/VCO2 slope of ≥34 was associated with less survival in CHF [17] and pulmonary hypertension [18] and with higher sensitivity rather than VO2 max. Torchio et al. [19] found that high VE/VCO2 slope of ≥34 is an independent predictor of postoperative mortality after lung resection for lung cancer. More recently, Brunelli et al. [20] found that VE/VCO2 slope of >35 was associated with higher rate of early (30 days) postoperative respiratory complications among COPD patients rather than VO2 max and they recommended its incorporation in the clinical practice for preoperative evaluation for lung resection. Our results are in keeping with those observations and extend the risk of cardiopulmonary complications during the year after surgery. Furthermore, we found that high VE/VCO2 slope of >35 denoting ventilatory inefficiency is a more relevant cause of poor survival in COPD patients eligible for lung resection than cancer-related mortality. We also observed that systolic blood pressure at maximal exercise was significantly higher among those who died postoperatively. This could be due to their higher resting hypertension despite not being statistically significant (Supplementary Table S4) or secondary to abnormal control of blood pressure [10].

Associated cardiovascular comorbidity was not found to be a risk factor of postoperative complications in our population, probably reflecting a selection of fitter patients; however, it is well known as a risk factor for perioperative complications and preoperative cardiac evaluation have been incorporated recently [21] in the assessment of the patients with lung cancer planned for surgical resection. Similarly, neither age nor the extent of pulmonary resection was associated with postoperative complications in our population, as has been previously suggested by some authors [1].

Clinical implications

The present study showed first that ventilator efficiency as expressed by VE% predicted, VE/VCO2 slope and VO2 (l/min) is an important predictor of the overall postoperative event including complications and mortality. We suggest that these parameters are more reliable in the patient stratification especially among those with COPD and should not be ignored in the preoperative evaluation. Secondly, we assumed that COPD patients with lung cancer and VE/VCO2 slope of >35 could benefit from optimal pharmacological treatment and pulmonary rehabilitation programme preoperatively with risk reduction of postoperative complications. Recent studies showed that COPD with lung cancer undergoing surgical treatment got benefit from preoperative pulmonary rehabilitation and VO2 max improved significantly [22]. Furthermore, therapeutic hyperoxia in resting normoxic COPD could change perioperative risk stratification as it was associated with significant improvement in VO2 max and decreased VE/VCO2 slope [23].

Study limitations

The current study has some limitations. First, we could not analyse the different CPET parameters in relation to mortality separately due to the limited number of postoperative mortality (only 2 patients) and we used the overall postoperative events for the identification of dependent risk factors. However, we provided a comparison between postoperative complications and mortality including both baseline characteristics and different CPET parameters. Secondly, we did not take into consideration the estimated PPO (VO2 max) in the comparison between the development of postoperative complications and its absence and we used only the measured VO2 max. Bolliger et al. [24] found that calculated PPO (VO2 max) was a reliable factor for predicting postoperative pulmonary complications. However, a meta-analysis of 14 studies confirmed the strong relationship between measured VO2 max during CPET and the occurrence of postoperative complications and it was accepted in the last updated guidelines for the physiological evaluation of lung cancer patient [3]. Lastly, the number of events analysed in the current study was low. However, this low number (23 events, 45%) did not affect the power of a survival analysis as at least 10 events are needed to be observed for each covariate considered that is not related to the number of participants [25].

CONCLUSIONS

Forty-five percent of COPD patients undergoing lung resection surgery had some form of complications during the following year despite an appropriate risk stratification using CPET. VO2 max failed to be a good predictor of events by itself, and markers of ventilator inefficiency, especially a VE/VCO2 slope higher than 35, and work load as well as baseline VE/VCO2 slope are independently associated with an increased risk of postoperative complications or mortality.

SUPPLEMENTARY MATERIAL

Supplementary material is available at EJCTS online.

Funding

This study was funded by Direcció General d’Investigació i desenvolupament tecnològic de la Conselleria d’Innovació, Interior i Justícia de la Comunitat Autònoma de les Illes Balears and Fondos FEDER [Grupos competitivos (PRE-R-22528-2011)].

Conflict of interest: Hanaa Shafiek was granted by the University of Alexandria and Ministry of Higher Education of Egypt as member of ParOwn (the Partnership and Ownership initiative).

ACKNOWLEDGEMENTS

Authors are grateful to all the Lung Function Unit team for their contribution to the logistics of the study.

REFERENCES

1

Licker
MJ
,
Widikker
I
,
Robert
J
,
Frey
JG
,
Spiliopoulos
A
,
Ellenberger
C
et al. .
Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends
.
Ann Thorac Surg
2006
;
81
:
1830
7
.

2

Smith
TP
,
Kinasewitz
GT
,
Tucker
WY
,
Spillers
WP
,
George
RB
.
Exercise capacity as a predictor of post-thoracotomy morbidity
.
Am Rev Respir Dis
1984
;
129
:
730
4
.

3

Brunelli
A
,
Kim
AW
,
Berger
KI
,
Addrizzo-Harris
DJ
.
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
.
Chest
2013
;
143
(5 Suppl)
:
e166S
90S
.

4

Benzo
RP
,
Sciurba
FC
.
Oxygen consumption, shuttle walking test and the evaluation of lung resection
.
Respiration
2010
;
80
:
19
23
.

5

Colice
GL
,
Shafazand
S
,
Griffin
JP
,
Keenan
R
,
Bolliger
CT
.
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition)
.
Chest
2007
;
132
(3 Suppl)
:
161S
77S
.

6

Bechard
D
,
Wetstein
L
.
Assessment of exercise oxygen consumption as preoperative criterion for lung resection
.
Ann Thorac Surg
1987
;
44
:
344
9
.

7

Brunelli
A
,
Belardinelli
R
,
Refai
M
,
Salati
M
,
Socci
L
,
Pompili
C
et al. .
Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection
.
Chest
2009
;
135
:
1260
7
.

8

Win
T
,
Jackson
A
,
Sharples
L
,
Groves
AM
,
Wells
FC
,
Ritchie
AJ
et al. .
Cardiopulmonary exercise tests and lung cancer surgical outcome
.
Chest
2005
;
127
:
1159
65
.

9

Vestbo
J
,
Hurd
SS
,
Agusti
AG
,
Jones
PW
,
Vogelmeier
C
,
Anzueto
A
et al. .
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
.
Am J Respir Crit Care Med
2013
;
187
:
347
65
.

10

American Thoracic Society; American College of Chest Physicians.ATS/ACCP statement on cardiopulmonary exercise testing
.
Am J Respir Crit Care Med
2003
;
167
:
211
77
.

11

Jones
NL
,
Makrides
L
,
Hitchcock
C
,
Chypchar
T
,
McCartney
N
.
Normal standards for an incremental progressive cycle ergometer test
.
Am Rev Respir Dis
1985
;
131
:
700
8
.

12

Stanzani
F
,
Paisani Dde
M
,
Oliveira
A
,
Souza
RC
,
Perfeito
JA
,
Faresin
SM
.
Morbidity, mortality, and categorization of the risk of perioperative complications in lung cancer patients
.
J Bras Pneumol
2014
;
40
:
21
9
.

13

Ferguson
MK
,
Little
L
,
Rizzo
L
,
Popovich
KJ
,
Glonek
GF
,
Leff
A
et al. .
Diffusing capacity predicts morbidity and mortality after pulmonary resection
.
J Thorac Cardiovasc Surg
1988
;
96
:
894
900
.

14

Campione
A
,
Terzi
A
,
Bobbio
M
,
Rosso
GL
,
Scardovi
AB
,
Feola
M
.
Oxygen pulse as a predictor of cardiopulmonary events in lung resection
.
Asian Cardiovasc Thorac Ann
2010
;
18
:
147
52
.

15

Brunelli
A
,
Pompili
C
,
Belardinelli
R
.
Beyond peak VO2: ventilatory inefficiency (VE/VCO2 slope) measured during cardiopulmonary exercise test to refine risk stratification in lung resection candidates
.
Eur J Cardiothorac Surg
2010
;
38
:
19
20
.

16

Zhao
L
,
Peng
L
,
Wu
B
,
Bu
X
,
Wang
C
.
Effects of dynamic hyperinflation on exercise capacity and quality of life in stable COPD patients
.
Clin Respir J
2016
;
10
:
579
88
.

17

Guazzi
M
,
De Vita
S
,
Cardano
P
,
Barlera
S
,
Guazzi
MD
.
Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure
.
Am Heart J
2003
;
146
:
542
8
.

18

Schwaiblmair
M
,
Faul
C
,
von Scheidt
W
,
Berghaus
TM
.
Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension
.
BMC Pulm Med
2012
;
12
:
23
.

19

Torchio
R
,
Guglielmo
M
,
Giardino
R
,
Ardissone
F
,
Ciacco
C
,
Gulotta
C
et al. .
Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer
.
Eur J Cardiothorac Surg
2010
;
38
:
14
9
.

20

Brunelli
A
,
Belardinelli
R
,
Pompili
C
,
Xiume
F
,
Refai
M
,
Salati
M
et al. .
Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection
.
Ann Thorac Surg
2012
;
93
:
1802
6
.

21

Brunelli
A
,
Charloux
A
,
Bolliger
CT
,
Rocco
G
,
Sculier
JP
,
Varela
G
et al. .
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
.
Eur Respir J
2009
;
34
:
17
41
.

22

Stefanelli
F
,
Meoli
I
,
Cobuccio
R
,
Curcio
C
,
Amore
D
,
Casazza
D
et al. .
High-intensity training and cardiopulmonary exercise testing in patients with chronic obstructive pulmonary disease and non-small-cell lung cancer undergoing lobectomy
.
Eur J Cardiothorac Surg
2013
;
44
:
e260
5
.

23

Womble
HM
,
Schwartzstein
RM
,
Johnston
RP
,
Roberts
DH
.
Effect of therapeutic hyperoxia on maximal oxygen consumption and perioperative risk stratification in chronic obstructive pulmonary disease
.
Lung
2012
;
190
:
263
9
.

24

Bolliger
CT
,
Wyser
C
,
Roser
H
,
Soler
M
,
Perruchoud
AP
.
Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications
.
Chest
1995
;
108
:
341
8
.

25

Bradburn
MJ
,
Clark
TG
,
Love
SB
,
Altman
DG
.
Survival analysis Part III: multivariate data analysis—choosing a model and assessing its adequacy and fit
.
Br J Cancer
2003
;
89
:
605
11
.

Supplementary data